Venous thrombosis causes an estimated 50,000 deaths per year in the US and has an incidence of 1 per 1000 annually. There are many reported risk factors including a genetic element that can contribute to thrombosis. Cardiovascular disease is a leading cause of death for both men and women in most racial ethnic groups.
TRP-F
The Elucigene TRP-F (Thrombosis Risk Panel-Fluorescent) is a recently developed kit that provides laboratories with a simple and accurate means of routinely testing for the three most relevant mutations implicated in the risk of developing venous thromboembolism. Elucigene TRP-F is provided as a single mix that only requires the addition of patient DNA for rapid analysis on the Applied Biosystems 3*** series Genetic Analyzers..
The factor V Leiden (R506Q) mutation is the most common inherited form of thrombophilia, but the Prothrombin 20210A (factor II) and MTHFR (methylenetetrahyrofolate reductase) C677T also contribute toward increased risk.
• How to Order • Cat. No. THF03B2
NOTE: Elucigene TRP is also offered as a gel based assay (TH003B2) for analysis of factor V Leiden (R506Q), Prothrombin 20210A (factor II) and MTHFR (methylenetetrahyrofolate reductase) C677T. See the Gel Based Kits setion of this website for further details.
Elucigene TRP-F is not available for sale in the United States
Please note: Licences for the in vitro diagnostic analysis of gene mutations detected by these reagents may be required and are the responsibility of the reagent purchaser.
